Symmetry Partners’s Edwards Lifesciences EW Stock Holding History

Symmetry Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$269K	Buy	+2,969	New	+$249K	0.01%	196
2024 Q3	–	Sell	-3,453	Closed	-$319K	–	234
2024 Q2	$319K	Hold	3,453	–	–	0.02%	393
2024 Q1	$330K	Hold	3,453	–	–	0.03%	393
2023 Q4	$265K	Hold	3,453	–	–	0.01%	430
2023 Q3	$239K	Sell	3,453 -582	-14%	-$46.8K	0.01%	475
2023 Q2	$381K	Hold	4,035	–	–	0.02%	408
2023 Q1	$334K	Sell	4,035 -2,592	-39%	-$204K	0.02%	430
2022 Q4	$494K	Sell	6,627 -783	-11%	-$60.3K	0.03%	334
2022 Q3	$612K	Hold	7,410	–	–	0.04%	256
2022 Q2	$705K	Hold	7,410	–	–	0.05%	234
2022 Q1	$872K	Hold	7,410	–	–	0.05%	221
2021 Q4	$960K	Hold	7,410	–	–	0.06%	222
2021 Q3	$806K	Hold	7,410	–	–	0.05%	273
2021 Q2	$767K	Sell	7,410 -516	-7%	-$48.6K	0.05%	291
2021 Q1	$663K	Sell	7,926 -216	-3%	-$18.3K	0.05%	313
2020 Q4	$743K	Sell	8,142 -1,041	-11%	-$86.3K	0.06%	255
2020 Q3	$733K	Buy	9,183 +1,822	+25%	+$142K	0.06%	223
2020 Q2	$509K	Sell	7,361 -2,914	-28%	-$207K	0.06%	147
2020 Q1	$646K	Buy	10,275 +648	+7%	+$46.7K	0.14%	74
2019 Q4	$749K	Buy	9,627 +5,052	+110%	+$394K	0.15%	87
2019 Q3	$335K	Buy	4,575 +684	+18%	+$48K	0.07%	236
2019 Q2	$240K	Sell	3,891 -2,667	-41%	-$161K	0.05%	283
2019 Q1	$418K	Buy	6,558 +2,529	+63%	+$144K	0.07%	181
2018 Q4	$206K	Buy	+4,029	New	+$204K	0.05%	235

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Symmetry Partners's EW Position: Q2 2026 in Review

Symmetry Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 2,969 shares worth $269K. The stake represents 0.01% of the portfolio and ranks #196 among its holdings. This is a return to the name: Symmetry Partners previously reported a position in EW as recently as Q2 2024.

Symmetry Partners first reported a position in EW in Q4 2018 and has held it in 24 quarters since. The position peaked at $960K in Q4 2021. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Symmetry Partners held 2,969 shares of Edwards Lifesciences worth $269K as of Q2 2026.
Edwards Lifesciences was a new Symmetry Partners position in Q2 2026.
Edwards Lifesciences made up 0.01% of Symmetry Partners's portfolio in Q2 2026, its #196 holding.
Symmetry Partners first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 24 quarters since.
Symmetry Partners's Edwards Lifesciences position peaked at $960K in Q4 2021.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Symmetry Partners's 13F filing for Q2 2026, filed 23 Jul 2026.